[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"esrd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:esrd":53},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,39,70,112,142,167],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100553550","repletion-of-ergothioneine-in-patients-with-kidney-failure-100553550",false,"NCT06487546","Repletion of Ergothioneine in Patients With Kidney Failure","Inclusion Criteria:\n\n* kidney failure receiving hemodialysis or peritoneal dialysis\n\nExclusion Criteria:\n\n* blood transfusion within 90 days\n* taking supplements which contain ergothioneine","ALL","18 Years",{"count":18,"type":19},28,"ESTIMATED","INTERVENTIONAL",[22],"NA","Dialysis removes potentially harmful chemicals from the blood but can also remove potentially valuable chemicals. One potentially valuable chemical called ergothioneine, which comes from the diet, is low in the blood of people receiving dialysis. For this research study, the investigators hope to learn how well a daily ergothioneine supplement will replenish the levels in the blood of people with kidney failure.",[25],"Esrd","RECRUITING","2026-03-26",{"date":29,"type":30},"2026-04-01","ACTUAL",{"date":32,"type":30},"2025-04-01",{"date":34,"type":19},"2030-12",{"name":36,"class":37},"Stanford University","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":20,"phases":49,"briefSummary":51,"conditions":52,"keywords":55,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":38},"100586305","phase-2-effect-of-canagliflozin-on-ultrafiltration--fibrosis-in-patients-on-peritoneal-dialysis-100586305","NCT06913647","Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis","Effect of Canagliflozin on Ultrafiltration and Fibrosis in Peritoneal Dialysis: a a Proof-of-concept Randomized Phase II Crossover Clinical Trial","CAN-PD","Inclusion Criteria:\n\n* Adult patients with kidney failure on PD (both incident and prevalent) who are on a stable prescription of dextrose-based solutions for at least 3 months.\n* Only high or high-average transporters, as classified by PET, will be included.\n\nExclusion Criteria:\n\n* History of euglycemic ketoacidosis\n* Known hypersensitivity to canagliflozin\n* Active peritonitis or tunnel infection\n* Kidney transplant scheduled in the next 6 months\n* Severe liver cirrhosis (Child-Pugh class C stage)\n* Recurrent severe genital or urine infections\n* Patients receiving digoxin, phenobarbital, phenytoin, rifampin, or ritonavir if these agents cannot be safely discontinued\n* Pregnancy or breastfeeding",{"count":48,"type":19},30,[50],"PHASE2","This is a phase II, proof-of-concept, placebo-controlled, double-blind, cross-over randomized clinical trial, assessing the effect of canagliflozin on peritoneal membrane function in patients on PD.\n\nThe primary aim of this trial is to determine the short-term effects of canagliflozin, an SGLT-2 inhibitor, on glucose absorption by the peritoneal membrane and on ultrafiltration, as assessed by a standardized peritoneal equilibrium test. The secondary aims are to determine the effect of canagliflozin on solute clearance and on effluent biomarkers of inflammation, angiogenesis, and fibrosis at 26 weeks. We hypothesize that canagliflozin will prevent glucose absorption by the peritoneal membrane, as compared with placebo, and will attenuate the development of inflammation, angiogenesis, and fibrosis of the peritoneal membrane, as assessed by relevant biomarkers in the dialysate.",[53,54],"ESRD","CKD (Chronic Kidney Disease) Stage 5D",[56,57,58,59,60],"SGLT-2 inhibitors","Canagliflozin","Ultrafiltration failure","Peritoneal fibrosis","Peritoneal dialysis","2026-03-12",{"date":63,"type":30},"2026-03-16",{"date":65,"type":30},"2026-02-01",{"date":67,"type":19},"2028-12-31",{"name":69,"class":37},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":20,"phases":79,"briefSummary":80,"conditions":81,"keywords":91,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":18},"100516231","save-fistulas-the-selfwrap-assisted-arteriovenous-fistulas-study-100516231","NCT06001827","SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study","SAVE-FistulaS","Inclusion Criteria:\n\n* Age of at least 18 years\n* Referred for creation of a new AVF\n* Willing and able to comply with study requirements, communicate with the study team, and attend follow up visits over a period of 36 months\n\nExclusion Criteria:\n\n* Planned index procedure to revise or repair an existing fistula\n* Target artery inner diameter \\\u003C 2.0 mm, as measured by ultrasound while the target arm is under tourniquet pressure and anesthesia\n* Target vein inner diameter \\\u003C 2.0 mm, as measured by ultrasound while the target arm is under tourniquet pressure and anesthesia\n* Significant (at least 50%) stenosis at the target vein on the side of surgery (between the planned anastomosis site and the axillary vein), as diagnosed by preoperative ultrasound\n* Known central venous stenosis of at least 50% on the side of surgery\n* Presence of a stent or a stent graft within the access circuit\n* Known or suspected coagulation disorder that, in the opinion of the Investigator, puts too much risk on the patient for AVF creation\n* Known or suspected active infection at the time of surgery\n* Congestive heart failure NYHA class 4\n* Prior steal on the side of surgery;\n* Enrolled in another investigational drug, device, or biological study, or was previously enrolled in this study\n* Life expectancy less than 12 months\n* Expected to undergo kidney transplant surgery within 6 months of enrollment\n* Expected to undergo home hemodialysis\n* Females of childbearing potential (premenopausal and not surgically sterile) without documented current negative pregnancy test at screening\n* Presence of a comorbid condition that, in the opinion of the Investigator, may significantly confound the collection of safety and efficacy data in this study\n* Unwillingness or inability to give consent and\u002For comply with the study follow up schedule\n* Any health condition, which in the opinion of the Investigator, would interfere with the safety of the participant or the participant's ability to comply with the study.",{"count":78,"type":19},600,[22],"This is a prospective, randomized, multi-center clinical trial for chronic kidney disease (CKD) patients referred for creation of a new arteriovenous fistula (AVF) in order to assess the safety and effectiveness of SelfWrap, a bioabsorbable perivascular wrap.",[82,83,84,85,53,86,87,88,89,90],"Chronic Kidney Diseases","End Stage Renal Disease","Arteriovenous Fistula","Hemodialysis Access Failure","Vascular Access Complication","Renal Failure","Catheter Complications","Catheter Dysfunction","Renal Insufficiency",[92,93,94,95,96,97,98,99,100,83,84,101],"Vascular Surgery","Vascular Access","Nephrology","Bioabsorbable","Perivascular Wrap","External Support","Hemodialysis","Dialysis","Chronic Kidney Disease","AVF","2026-02-12",{"date":104,"type":30},"2026-02-17",{"date":106,"type":30},"2024-01-03",{"date":108,"type":19},"2029-12",{"name":110,"class":111},"VenoStent","INDUSTRY",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":20,"phases":122,"briefSummary":124,"conditions":125,"keywords":129,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":38},"100544234","phase-1-adding-urea-to-the-final-dialysis-fluid-100544234","NCT06366230","Adding Urea to the Final Dialysis Fluid","Adding Urea to the Final Dialysis Fluid in Order to Prevent Dialysis Disequilibrium in Patients Who Need Aggressive Dialysis for Electrolyte Abnormalities","Urea dialysate","Inclusion Criteria:\n\n* Serum Urea \\> 120\n* Serum Potassium \\> 5.5 or serum CO2 \\\u003C 15 or need for aggressive dialysis due to toxic ingestion\n* need for dialysis\n\nExclusion Criteria:\n\n* Pediatric\n* need for CRRT",{"count":121,"type":19},20,[123,50],"PHASE1","At times patients with advanced renal failure present with severe hyperkalemia or acidosis and very high serum blood urea nitrogen (BUN) concentrations. These patients cannot be dialyzed aggressively as the lowering of serum BUN may results in disequilibrium syndrome but on the other hand they need aggressive dialysis in order to lower their serum potassium or fix their severe acidosis. If one is able to add urea to the dialysis fluid, one can prevent the rapid lowering of serum BUN and osmolality at the same time as doing aggressive dialysis to lower serum potassium and\u002For fix the metabolic acidosis.",[126,53,127,128],"Dysequilibrium Syndrome","Hyperkalemia","Metabolic Acidosis",[53,130,131,132,133],"Urea","Disequilibrium","Potassium","Acid\u002Fbase","2026-02-09",{"date":102,"type":30},{"date":137,"type":30},"2025-09-16",{"date":139,"type":19},"2028-06-30",{"name":141,"class":37},"University of California, San Francisco",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":20,"phases":152,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":166},"100465317","phase-3-safety-of-regional-citrate-anticoagulation-sarca-study-100465317","NCT05339139","SAfety of Regional Citrate Anticoagulation (SARCA Study)","An Open-label, Prospective, Multicenter Study to Assess the SAfety of Regional Citrate Anticoagulation Delivered by the multiFiltratePRO System in Adult Patients Requiring Continuous Renal Replacement Therapy (SARCA Study)","SARCA","Inclusion Criteria:\n\n1. Signed informed consent form by\n\n   * The subject or\n   * A legally authorized representative (LAR), if the subject is unable to consent\n2. Adult patients ≥ 18 years old\n3. Diagnosis of AKI or End-Stage Kidney Disease (ESKD) requiring CRRT\n4. Vascular access - Dialysis Catheter with size and location per institutional practice\n\nExclusion Criteria:\n\n1. Metabolic alkalosis as defined by serum bicarbonate greater than 30 mmol\u002FL and arterial pH greater than 7.55\n2. A female who is pregnant or breast feeding\n3. Severe liver disease defined as International Normalized Ratio (INR) greater than 2.0 and total bilirubin greater than 5 mg\u002Fdl, and both aspartate aminotransferase (AST) and alanine aminotransferase (ALT) greater than 3 times upper limit of normal\n4. Subjects currently enrolled in or who have completed any other investigational drug or device study within last 30 days prior to signing informed consent\n5. Previous participation in a similar or the same study.\n6. Subjects already on continuous renal replacement therapy\n7. Subjects with active COVID-19 infection\n8. Subjects cannot tolerate citrate therapy defined as severe liver disease (see exclusion criteria #3), shock with muscle hypoperfusion and known hypersensitivity to citrate",{"count":151,"type":19},50,[153],"PHASE3","This is an Open-label, Prospective, Multicenter Study to Assess the SAfety of Regional Citrate Anticoagulation Delivered by the multiFiltratePRO system in Adult Patients Requiring Continuous Renal Replacement Therapy (SARCA Study).",[156,53],"Acute Kidney Injury","2025-04-23",{"date":159,"type":30},"2025-04-24",{"date":161,"type":30},"2023-10-17",{"date":163,"type":19},"2025-07-31",{"name":165,"class":111},"Fresenius Medical Care North America",10,{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":173,"targetDuration":175,"studyType":176,"phases":4,"briefSummary":177,"conditions":178,"keywords":180,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":38},"100284953","peritoneal-dialysis-registration-system-persist-100284953","NCT02989298","Peritoneal Dialysis Registration System (PERSIST)","Inclusion Criteria:PD patients -\n\nExclusion Criteria:No\n\n\\-",{"count":174,"type":19},10000,"10 Years","OBSERVATIONAL","Brief Summary: The investigators are registering all PD patients at recruited hospitals and developing a PD database in China. Patients will be followed up every 3 months, and both baseline and follow-up information will be collected and input into the registration system. The patient survival, technical survival, peritonitis rate, longitudinal changes of residual renal function and peritoneum function, and quality of life for PD patients, etc, will be compared using the PD database.",[53,179],"Disorders Associated With Peritoneal Dialysis",[181,182,183,184,185,186],"Peritoneal Dialysis (PD)","Residual renal function","Peritoneum function","Peritonitis rate","Technical survival","Patient survival","2020-10-20",{"date":189,"type":30},"2020-10-22",{"date":191,"type":4},"2013-12",{"date":193,"type":19},"2026-12",{"name":195,"class":37},"Sun Yat-sen University"]